Use of acetylcholinesterase inhibitors and memantine in Alzheimer-type dementia;Utilización de los inhibidores de la acetilcolinesterasa y la memantina para el tratamiento clínico de la demencia tipo Alzheimer

Revista Espanola de Salud Publica

Volumn 79, Issue 6, 2005, Pages 665-672

  Portela Romero, Manuel ^a,c   Pombo Romero, Julio ^a   Bugarín González, Rosendo ^b   Tasende Souto, Margarita ^a   Represa Veiga, Silvia ^a  

^a Productos Sanitarios de la Consejería de Sanidad de Galicia ^*  (Spain)

^b Servicio Gallego de Salud   (Spain)

^c Centro de Información Farmacoterapéutica   (Spain)

Author keywords

Alzheimer disease; Cholinesterase inhibitors; Galantamine; Memantine

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MEMANTINE; RIVASTIGMINE; CARBAMIC ACID DERIVATIVE; DOPAMINE RECEPTOR STIMULATING AGENT; INDAN DERIVATIVE; NEUROPROTECTIVE AGENT; NOOTROPIC AGENT; PIPERIDINE DERIVATIVE;

AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DATA BASE; DEMOGRAPHY; FEMALE; HEALTH SERVICE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICINAL PLANT; POPULATION; AGE; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; DRUG COMBINATION; MIDDLE AGED; SEX DIFFERENCE;

AGE FACTORS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; CROSS-SECTIONAL STUDIES; DOPAMINE AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GALANTAMINE; HUMANS; INDANS; MALE; MEMANTINE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; NOOTROPIC AGENTS; PHENYLCARBAMATES; PIPERIDINES; SEX FACTORS;

EID: 33644855901     PISSN: 11355727     EISSN: 11355727     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Warner J, Butler R. Enfermedad de Alzheimer. Evid Clin 2002;1:829-843.
2. Perkins P, Annegers JF, Doody RS, Cooke N, Aday L, Vernon SW. Incidence and prevalence of dementia in a multiethnic cohort of municipal retirees. Neurology 1997; 49:44-50.
3. Bachman DL, Wolf PA, Linn R, Knoefel JE, Cobb J. Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study. Neurology 1992;42:115-119.
4. Fratiglioni L, Grut M, Forsell Y, Viitanen M, Grafstrom M. Prevalence of Alzheimer's disease and other dementias in an elderly urban population: relationship with age, sex, and education. Neurology 1991;41:1886-1892.
5. Folstein MF, Bassett SS, Anthony JC, Romanoski AJ, Nestadt GR. Dementia: case ascertainment in a community survey. J Gerontol 1991;46:132-138.
6. Jann M, Shirley K, Small G. Clinical pharmacokinetics and pharmaco-dynamics of cholinesterase inhibitors. Clin Pharmacokinet 2002;41:719-723.
7. Bonner L, Peskind E. Pharmacologic treatment of dementia. Med Clin North Am 2002; 86:657-74.
8. Centro Andaluz de Información de Medicamentos. Tratamiento de la enfermedad de Alzheimer ¿hay algo nuevo? Bol Ter Andal 2004; 20:17-20.
9. Committe for Proprietary Medicinal Products. European Public Assessment Report (EPAR). Axura®. European Agency for the Evaluation of Medicinal Products [en línea] URL disponible en 〈http://www.emea.eu.int/ humandocs/Humans/EPAR/axura/axura.htm〉. Citado el 10-5-2005].
10. Instituto Nacional de Estadística. Disponible en 〈http://www.ine.es Citado el 10-5-2005.
11. Servicio Gallego de salud. Base de datos SIAC-PF.
12. WHO Collaborating Centre for drug statistics methodology. Disponible en 〈http://www.whocc.no/atcddd/〉 Citado el 10-5-2005.
13. Broderick WC, Solis A, McRae T, Master V, Shah S. Donepezil versus rivastigmine utilization patterns in a retrospective claims analysis. Baltimore, USA: AGS Annual Scientific Meeting; 2003.
14. Sicras A, Rejas-Gutiérrez J. Patrón de persistencia de tratamientos anticolinesterásicos en la demencia de tipo Alzheimer: análisis comparativo retrospectivo del donepezilo, la rivastigmina y la galantamina. Rev Neurol 2004;39: 312-16.
15. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I; Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receveing donepezil: a randomized controlled trial. JAMA 2004;291:317-24.
16. Hartmann S, Mobius HJ. Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy. Int Clin Psychopharmacol 2003 Mar;18:81-5.
17. Bermejo F, Trincado R. ¿Cuántas demencias y casos de enfermedad de Alzheimer hay en España? Actual Neurol Neurocienc Envejec 2003;1:341-345.
18. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ. 2005 Aug 6;331(7512):321-7.